Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 4;18(3):604-616.
doi: 10.5114/aoms.2020.96052. eCollection 2022.

Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies

Jacek J Jóźwiak  1 , Sławomir Kasperczyk  2 , Tomasz Tomasik  3 , Tadeusz Osadnik  4 , Adam Windak  3 , Krzysztof Studziński  3 , Mirosław Mastej  5 , Alberico Catapano  6 , Kausik K Ray  7 , Dimitri P Mikhailidis  8 , Peter P Toth  9 , George Howard  10 , Gregory Y H Lip  11 , Maciej Tomaszewski  12 , Fadi J Charchar  13 , Naveed Sattar  14 , Bryan Williams  15 , Thomas M MacDonald  16 , Paweł Krzemień  17 , Michał Dobrakowski  2 , Aleksandra Kasperczyk  2 , Dariusz Nowak  18 , Łukasz Skowron  19 , Żaneta Żak  1 , Joanna Lewek  20 , Maciej Banach  20   21   22
Affiliations

Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies

Jacek J Jóźwiak et al. Arch Med Sci. .

Abstract

Introduction: Cardiovascular disease (CVD) is a major cause of morbidity and mortality throughout the world. The LIPIDOGRAM2015 study was performed to estimate the prevalence of risk factors for atherosclerotic diseases as well as cardiovascular and related disorders in the primary care setting in Poland. The LIPIDOGEN2015 sub-study was designed to include a random cohort of patients in order to analyse parameters related to lipid metabolism, oxidative stress, inflammatory responses, autoimmune disorders, and gene variants that confer susceptibility to cardiometabolic and atherosclerotic diseases.

Material and methods: The recruitment was carried out by 438 primary care physicians in Poland. The expected number of patients recruited for the LIPIDOGRAM2015 study was 13,000-14,000 with 13-15% (1700-2000) also participating in the LIPIDOGEN2015 sub-study. Each patient had to complete a questionnaire concerning medical and family history, concomitant diseases, and pharmacotherapy. Anthropometric measurements were performed at the doctor's office. For the LIPIDOGEN2015 sub-study, saliva samples for DNA isolation and blood samples for measurement of glycated haemoglobin, oxidative stress parameters, autoantibody levels, and inflammatory cytokine profile and apolipoprotein profile were collected. Follow-up data will be obtained from the National Health Fund in Poland.

Results: The LIPIDOGRAM2015 and LIPIDOGEN2015 study cohort reflects the prevalence of cardiovascular risk factors and concomitant diseases, markers of oxidative stress, the presence of autoantibodies, inflammatory cytokine profile, and apolipoprotein profile, as well as genetic variants potentially conferring susceptibility to cardiometabolic and atherosclerotic diseases.

Conclusions: This study presents the prevalence of different CV risk factors, with special emphasis on lipid disorders, and it assesses the relationship between inflammation, oxidative stress, and mutations in genes encoding proteins regulating lipid metabolism, as well as genes conferring susceptibility to cardiovascular, cardiometabolic, and related diseases.

Keywords: atherosclerosis; cardiometabolic diseases; cardiovascular diseases; dyslipidaemia; genes; inflammation; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

JJJ has received research grant/support from Valeant and has served as a consultant or speaker for Valeant, Amgen, Teva, Servier, Boehringer Ingelheim, Celgene, Bioton, Microlife, and ALAB Laboratories. MB has received research grant(s)/support from Sanofi and Valeant and has served as a consultant for Akcea, Amgen, Daiichi-Sankyo, KRKA, MSD, Mylan, Polfarmex, Polpharma, Sanofi-Aventis, Servier, Esperion, and Resverlogix. SK has served as a speaker for Novartis. GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo, and Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees were directly received personally. DPM has given talks, acted as a consultant, or attended conferences sponsored by Amgen, Novo Nordisk, and Libytec. PPT has served as a speaker for Amarin, Amgen, Esperion, Novo-Nordisk; consultant to Amarin, Amgen, Novartis, Resverlogix, and Theravance. TT has served as a consultant or speaker for Boehringer Ingelheim, Novartis, Shire, Biofarm, and Eli Lilly.

Figures

Figure 1
Figure 1
LIPIDOGRAM2015 and LIPIDOGEN2015 flowchart
None
See this image and copyright information in PMC

References

    1. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol 2018; 100: 1-19. - PubMed
    1. Khan MF, Wang G. Environmental agents, oxidative stress and autoimmunity. Curr Opin Toxicol 2018; 7: 22-7. - PMC - PubMed
    1. Adam S, Mohammad JB, Ho JH, et al. . Hypercholesterolaemia – practical information for non-specialists. Arch Med Sci 2018; 14: 1-21. - PMC - PubMed
    1. Quispe R, Hendrani AD, Baradaran-Noveiry B, et al. . Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the very large database of Lipids studies 6 and 7. Arch Med Sci 2019; 15: 1195-202. - PMC - PubMed
    1. Tomasik T, Jozwiak J, Windak A, et al. . Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study. Eur J Cardiovasc Prev Rehabil 2011; 18: 287-96. - PubMed